• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Stents

Reva wins CE Mark for bioresorbable scaffold in below-the-knee PAD

July 26, 2018 By Fink Densford

Reva Medical

Reva Medical (ASX:RVA) said yesterday it won CE Mark approval in the European Union for its Motiv bioresorbable drug-eluting scaffold, now cleared for treatment of below-the-knee peripheral artery disease. The San Diego-based company’s Motiv is made from the company’s proprietary radiopaque Tyrocore polymer designed for vascular scaffolds. Reva said that over the coming months, it will […]

Filed Under: Drug-Device Combinations, Featured, Regulatory/Compliance, Stents, Vascular Tagged With: Reva Medical

Medtronic touts early vessel healing in independent 1-month Resolute Onyx DES trial

May 24, 2018 By Fink Densford

Medtronic

Medtronic (NYSE:MDT) today released data from an independent study of its Resolute Onyx drug-eluting stent, touting strong early vessel healing at one month in a patient population with a high percentage of patients with complex coronary artery disease. Data from the study was presented at the EuroPCR Annual Meeting in Paris, the Fridley, Minn.-based company said. […]

Filed Under: Drug-Device Combinations, Featured, Stents, Vascular Tagged With: Medtronic

MIT study reveals the problem with bioresorbable stents

March 15, 2018 By Sarah Faulkner

MIT stent

Bioresorbable coronary scaffolds, designed to avoid the risks associated with the long-term implantation of metal stents, once captured the attention of medtech giants like Abbott (NYSE:ABT) and Boston Scientific (NYSE:BSX). But companies have since linked the use of these biodegradable polymer-based devices to a heightened risk of myocardial infarction and thrombosis, prompting Abbott to pull its Absorb […]

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals, Research & Development, Stents, Vascular Tagged With: abbott, Boston Scientific, Massachusetts Institute of Technology, National Institutes of Health

 India’s NPPA cuts prices on drug-eluting stents by nearly 8%

February 12, 2018 By Fink Densford

India's National Pharmaceutical Pricing Authority

India’s National Pharmaceutical Pricing Authority cut prices on stents yet again, dropping the cost of certain stents by about 7.6%, according to a Reuters report. This time, the prices on drug releasing stents were cut from approximately $469.60 (INR ₹30,180) to $433.82 (INR ₹27,890), according to the report. The new price cap comes as somewhat […]

Filed Under: Business/Financial News, Featured, Stents Tagged With: Indian National Pharmaceutical Pricing Authority (NPPA)

Cordis, Medinol win FDA nod for Elunir drug-eluting stent

November 30, 2017 By Sarah Faulkner

Cordis, Medinol

Cordis and Medinol announced today that the FDA approved its Elunir drug-eluting stent for the treatment of patients with narrowing or blocked coronary arteries. The stent, designed by Medinol and distributed exclusively by Cordis in the U.S., features a novel metallic spring tip and the narrowest strut width of any stent on the market in […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Regulatory/Compliance, Stents, Vascular, Wall Street Beat Tagged With: cordis, medinol

Price caps to keep Abbott’s Xience Sierra off the Indian market

November 3, 2017 By Brad Perriello

Abbott

Abbott (NYSE:ABT) reportedly won’t introduce its next-generation drug-eluting stent, the Xience Sierra, to the Indian market due to price caps there. The everolimus-eluting coronary stent, which won CE Mark approval in the European Union this week, is designed to allow cardiologists to treat the complex lesions that make up roughly 70% of cases. It offers […]

Filed Under: Featured, Stents Tagged With: abbott

Biotronik’s Orsiro drug-eluting stent succeeds at five-year follow-up

November 2, 2017 By Sarah Faulkner

Biotronik's Orsiro

Biotronik touted long-term safety and efficacy data for its Orsiro drug-eluting stent yesterday at this year’s Transcatheter Cardiovascular Therapeutics meeting. Data from the Bioflow-II trial and the Bioflow-III registry demonstrated that Biotroniks’s device boasts strong safety and clinical performance at five years, the company reported. In the 268-patient group treated with Orsiro, 60-month data from […]

Filed Under: Cardiovascular, Clinical Trials, Drug-Device Combinations, Featured, Stents, Vascular, Wall Street Beat Tagged With: abbott, Biotronik

TCT 2017: OrbusNeich’s dual therapy stent non-inferior to Abbott’s Xience DES in 1-year follow-up

October 31, 2017 By Sarah Faulkner

OrbusNeich

OrbusNeich touted results today from a pivotal registration study comparing its Combo dual therapy stent with Abbott‘s (NYSE:ABT) Xience stent in patients with ischemic heart disease. The trial is designed to evaluate the effectiveness of OrbusNeich’s combined endothelial progenitor cell capture and drug-eluting stent. The data showed that the device is non-inferior to Abbott’s drug-eluting […]

Filed Under: Cardiovascular, Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Stents, Vascular, Wall Street Beat Tagged With: abbott, OrbusNeich

Elixir Medical unveils ‘bioadaptive’ metallic drug-eluting stent at TCT 2017

October 31, 2017 By Sarah Faulkner

Elixir Medical DynamX

Interventional cardiologists have used stents to keep the heart’s coronary arteries open for decades. Transitioning from bare-metal stents to drug-eluting stents in the early 2000s brought tremendous benefits for patients. “But over the last 10 years, the technological progress and meaningful clinical improvements have plateaued,” Elixir Medical CEO Motasim Sirhan told Drug Delivery Business News. “When you stent an artery […]

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals, Stents, Vascular Tagged With: Elixir Medical Corporation

TCT 2017: Abbott’s Xience coronary stent helps patients feel better faster than open-heart surgery

October 30, 2017 By Sarah Faulkner

Abbott

Abbott (NYSE:ABT) reported today that patients who were treated with the company’s Xience coronary stent for left-main coronary artery disease felt better faster compared to patients who had open-heart surgery. The data were presented at this year’s Transcatheter Cardiovascular Therapeutics meeting during a late-breaking session. “For any treatment, it’s important to not only consider clinical outcomes […]

Filed Under: Cardiovascular, Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Stents, Wall Street Beat Tagged With: abbott

  • « Go to Previous Page
  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Go to page 4
  • Go to page 5
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS